الفهرس | Only 14 pages are availabe for public view |
Abstract Although breast carcinoma had many targeted biomarkers for its treatment, it is a heterogenous disease with different outcomes and needs new markers. Programmed death-ligand 1 (PDL1) is a new target with unclear role. The aim of this study was to examine the prevalence of PDL1 in early-stage invasive breast carcinoma and to elucidate its relation to tumor infiltrating lymphocytes (cytotoxic T-cells and regulatory T-cells), breast carcinoma subtypes, established clinicopathological factors, disease-free survival and overall survival. Material and Methods: One hundred and nine cases of early-stage invasive breast carcinoma were evaluated for age, grade, tumor size, stage and node status. Also, they were retrieved immunohistochemically for estrogen receptor, progesterone receptor, Her2/neu and Ki-67 then classified into five molecular subtypes. PDL1, FOXP3 and CD8 immunostaining were done and analyzed for all studied cases. PDL1 expression was correlated with two types of tumor infiltrating lymphocytes (CD8+ cytotoxic T-cells and FOXP3+ regulatory T-cells), histopathological factors, breast cancer subtypes, disease-free survival and overall survival. Results: PDL1 was expressed in 11% of the studied cases. It was significantly associated with high grade tumors and FOXP3+ regulatory T cells while it revealed reverse relation to CD8+ cytotoxic T-cells. It was also expressed in a reasonable number of triple negative breast carcinoma (16.1%) with no significant relation to different molecular subtypes. PDL1 |